UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 Trial

Antimicrobial Agents and Chemotherapy, 2010-02, Vol.54 (2), p.614-619

2010

Volltextzugriff (PDF)

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features

Clinical microbiology and infection, 2011-04, Vol.17 (4), p.557-565

2011

Volltextzugriff (PDF)

The Emergence of Linezolid Resistance among Enterococci in Intestinal Microbiota of Treated Patients Is Unrelated to Individual Pharmacokinetic Characteristics

Antimicrobial agents and chemotherapy, 2014-05, Vol.58 (5), p.2681-2687

2014

Volltextzugriff (PDF)

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

British journal of clinical pharmacology, 2007-11, Vol.64 (5), p.603-612

2007

Volltextzugriff (PDF)

Joint Population Pharmacokinetic Analysis of Zidovudine, Lamivudine, and Their Active Intracellular Metabolites in HIV Patients

Antimicrobial Agents and Chemotherapy, 2011-07, Vol.55 (7), p.3423-3431

2011

Volltextzugriff (PDF)

Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package

Anticancer research, 1994-11, Vol.14 (6A), p.2321

1994

Volltextzugriff (PDF)

Effect of oseltamivir, zanamivir or oseltamivir― zanamivir combination treatments on transmission of influenza in households

Antiviral therapy, 2012-01, Vol.17 (6), p.1085-1090

2012

Volltextzugriff (PDF)

Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV‐infected patients on HAART

British journal of clinical pharmacology, 2005-10, Vol.60 (4), p.390-403

2005

Volltextzugriff (PDF)

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

British journal of clinical pharmacology, 1997-11, Vol.44 (5), p.447-453

1997

Volltextzugriff (PDF)

Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children

Journal of pharmacokinetics and pharmacodynamics, 2001-06, Vol.28 (3), p.299-319

2001

Volltextzugriff (PDF)

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients

British journal of clinical pharmacology, 2008-04, Vol.65 (4), p.548-557

2008

Volltextzugriff (PDF)

Bayesian design criteria : computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model

Journal of pharmacokinetics and biopharmaceutics, 1995-02, Vol.23 (1), p.101-125

1995

Volltextzugriff (PDF)

Robust optimal design for the estimation of hyperparameters in population pharmacokinetics

Journal of pharmacokinetics and biopharmaceutics, 1998-12, Vol.26 (6), p.689-716

1998

Volltextzugriff (PDF)

Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis : An application to basiliximab in renal transplantation

Journal of pharmacokinetics and biopharmaceutics, 1999-04, Vol.27 (2), p.213-230

1999

Volltextzugriff (PDF)

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6‐an evaluation with the nonparametric maximum likelihood method

British journal of clinical pharmacology, 1994-11, Vol.38 (5), p.453-462

1994

Volltextzugriff (PDF)

Modelling and simulation in the development and use of anti-cancer agents : An underused tool?

Journal of pharmacokinetics and pharmacodynamics, 2004-12, Vol.31 (6), p.419-440

2004

Volltextzugriff (PDF)

Optimal sampling times for bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring

Journal of pharmacokinetics and biopharmaceutics, 1999-02, Vol.27 (1), p.85-101

1999

Volltextzugriff (PDF)

Non-linear mixed effects modeling : From methodology and software development to driving implementation in drug development science

Journal of pharmacokinetics and pharmacodynamics, 2005-04, Vol.32 (2), p.161-183

2005

Volltextzugriff (PDF)

Optimization of individual and population designs using Splus

Journal of pharmacokinetics and pharmacodynamics, 2003-12, Vol.30 (6), p.417-443

2003

Volltextzugriff (PDF)

Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method

Journal of pharmacokinetics and biopharmaceutics, 1998-04, Vol.26 (2), p.133-161

1998

Volltextzugriff (PDF)

Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine

Journal of pharmacokinetics and biopharmaceutics, 1988-06, Vol.16 (3), p.311-327

1988

Volltextzugriff (PDF)

Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients

British journal of clinical pharmacology, 2005-01, Vol.59 (1), p.18-27

2005

Volltextzugriff (PDF)

Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs

Antimicrobial Agents and Chemotherapy, 2004-01, Vol.48 (1), p.172-175

2004

Volltextzugriff (PDF)

The use of population pharmacokinetics in drug development

Clinical pharmacokinetics, 1996-02, Vol.30 (2), p.81-93

1996

Volltextzugriff (PDF)

Emergence of Resistance in Normal Human Aerobic Commensal Flora during Telithromycin and Amoxicillin-Clavulanic Acid Treatments

Antimicrobial Agents and Chemotherapy, 2003-06, Vol.47 (6), p.2030-2035

2003

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

KollektionTaylor & Francis:Master (3349 titles)

ThemaPhysical Sciences

ThemaPharmacology. Drug Treatments

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(29)
Medical Sciences
(29)
Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Pharmacology & Pharmacy
(26)
Humans
(25)
Male
(15)
Adult
(14)
Female
(14)
Pharmacokinetics
(13)
Middle Aged
(12)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(10)
Aged
(8)
Models, Biological
(8)
General Pharmacology
(7)
Infectious Diseases
(7)
Pharmacokinetics. Pharmacogenetics. Drug-Receptor Interactions
(7)
Microbiology
(6)
Aged, 80 And Over
(5)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 Trial

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features

The Emergence of Linezolid Resistance among Enterococci in Intestinal Microbiota of Treated Patients Is Unrelated to Individual Pharmacokinetic Characteristics

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

Joint Population Pharmacokinetic Analysis of Zidovudine, Lamivudine, and Their Active Intracellular Metabolites in HIV Patients

Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package

Effect of oseltamivir, zanamivir or oseltamivir― zanamivir combination treatments on transmission of influenza in households

Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV‐infected patients on HAART

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients

Bayesian design criteria : computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model

Robust optimal design for the estimation of hyperparameters in population pharmacokinetics

Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis : An application to basiliximab in renal transplantation

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6‐an evaluation with the nonparametric maximum likelihood method

Modelling and simulation in the development and use of anti-cancer agents : An underused tool?

Optimal sampling times for bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring

Non-linear mixed effects modeling : From methodology and software development to driving implementation in drug development science

Optimization of individual and population designs using Splus

Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method

Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine

Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients

Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs

The use of population pharmacokinetics in drug development

Emergence of Resistance in Normal Human Aerobic Commensal Flora during Telithromycin and Amoxicillin-Clavulanic Acid Treatments

Aktive Filter

Suchergebnisse filtern